The Trump administration released more than 80,000 documents today about the assassinations of former President John F. Kennedy, Robert F. Kennedy, and Martin Luther King Jr. The move is a result of an executive order Trump signed after being sworn in.
The Trump administration has released what it is calling “all of the files” the government has in its possession related to the assassination of former U.S. President John F. Kennedy.
The documents were made available on Tuesday through the National Archives. “In accordance with President Donald Trump’s directive of March 17, 2025, all records previously withheld for classification that are part of the President John F. Kennedy Assassination Records Collection are released,” it was announced.
Trump had announced Monday while at the John F. Kennedy Center for the Performing Arts in Washington, D.C., that the files would be released the following day.
“I am a man of my word,” he said, referring to his campaign promise to provide transparency on the matter.
Trump was at the center overseeing a board meeting. He has overhauled the organization during his first few weeks as president so it will host patriotic and pro-Christian events.
More than 80,000 documents were released. The move is a result of an executive order Trump signed just days after being sworn in on January 20. The order directed Director of National Intelligence Tulsi Gabbard to prepare a plan for the files’ release.
GOP Congresswoman Anna Paulina Luna of Florida announced in March the launch of a website that contains the new files. Click here to access it. Luna was tapped by the Trump administration to act as the head of a “task force” to oversee their rollout. She previously stated she believes there were “two shooters” of President Kennedy.
The contents of the files have been subject to speculation for decades following Kennedy’s death in November 1963. Various theories have been floated as to whether they would reveal who was motivated enough and who had the ability to carry out the attack.
Polls show most Americans do not believe the Warren Commission’s claim that assassin Lee Harvey Oswald acted alone. Alternative theories that have gained traction are that multiple shooters were strategically placed on top of several buildings in Dealey Plaza and that one on the “grassy knoll” in front of Kennedy to his right fired at him too.
The files released today also contain information about the 1968 assassination of Kennedy’s brother Robert Fr. Kennedy and activist Martin Luther King Jr.
Tucker Carlson discussed the files with former CNN host Chris Cuomo earlier this month.
“There’s clearly information in those files that are going to make the CIA look bad,” Cuomo argued.
“Just the CIA?” Carlson cryptically shot back, insinuating other entities may also be implicated.
In a podcast released in January, Carlson and ex-Washington Post reporter Jeffrey Morley noted that Trump’s former CIA chief Mike Pompeo, an outspoken Zionist, urged him to squash the release of the files in 2017. Congress had voted in 1992 to have the files made public in 2017.
At the end of their conversion, Carlson and Morley discussed the lesser-known fact that Kennedy was adamant about having inspections of Israel’s Dimona nuclear power plant. They also recalled how Kennedy was seeking to have the American Zionist Council (later the American-Israel Public Affairs Committee) register as a foreign entity.
Whether the files reveal a connection to the Israeli government will be more readily known once their contents are more thoroughly investigated.
Morley has taken to social media in recent weeks to explain how people can search the archived files related to Kennedy’s assassination. He has recommended they use the JFK Database Explorerhere.
Morley explains out on his Substack page that the National Archives has more than 3,800 records related to JFK on hand and that the FBI recently sent 2,400 additional files to the Archives for future release. He also notes that there are more than 319,000 documents comprising an estimated three million pages of material at the Archives II facility in College Park, Maryland.
Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.
The FDA old guard criticized the new leadership in a Dec. 3 New England Journal of Medicine (NEJM) letter over a higher regulatory bar for vaccines, namely the expectation that most new vaccine approvals will require randomized clinical trials, arguing it could hamper the market.
“Insisting on long, expensive outcomes studies for every updated formulation would delay the arrival of better-matched vaccines when new outbreaks emerge or when additional groups of patients could benefit,” the former commissioners wrote. “Abandoning the existing methods won’t ‘elevate vaccine science’ … It will subject vaccines to a substantially higher and more subjective approval bar.”
But while the former commissioners disclosed their conflicts of interest to the medical journal — per standard practice in scientific publishing — reporters didn’t relay them to the broader public in reports in the Washington Post, STAT News and CNN.
The headlines about a bipartisan rebuke from former occupants of FDA’s highest office give the impression that the Trump administration is contravening established science, but closer inspection reveals a revolving door between pharmaceutical corporations and the agencies overseeing them.
Three of the signatories have received payments totaling $6 million from manufacturers or former manufacturers of COVID vaccines.
Scott Gottlieb has received $2.1 million in cash and stock from his position on the Pfizer board of directors, where he has advised on ethics and regulatory compliance since 2019, according to company filings to the Securities and Exchange Commission. Stephen Ostroff has received $752,310 from Pfizer in consulting fees since 2020, according to OpenPayments.
Gottlieb and McClellan did not respond to requests for comment. Ostroff could not be reached for comment.
FDA Center for Biologics Evaluation and Research Director Vinay Prasad outlined the higher standards and shared the results of an internal analysis validating 10 reports of children’s deaths following the COVID-19 vaccine in a Nov. 28 memo to staff. He called for introspection and reform at the agency.
The NEJM letter criticizes Prasad for cracking down on a practice called “immunobridging” that infers vaccine efficacy from laboratory tests rather than assessing it through real-world reductions in disease or death. The FDA under the Biden administration expanded COVID vaccines to children using this “immunobridging” technique, extrapolating vaccine efficacy from adults to children based on antibody levels.
Norman Sharpless — who in addition to previously serving as acting FDA commissioner also served as the head of the National Institutes of Health’s National Cancer Institute — consults for Tempus, a company that collaborates with COVID vaccine maker BioNTech. He has helped steer $70 million in investments in biotech through a venture capital firm he founded in November 2024. Sharpless also disclosed $26,180 in payments in 2024 from Chugai Pharmaceutical, a Japanese pharmaceutical company that markets mRNA technology among other drugs, on OpenPayments.
“I was grateful for the opportunity to serve as NCI Director and Acting FDA Commissioner in the first Trump Administration, and strongly support many of the things President Trump is trying to do in the current Administration,” Sharpless said in an email.
Margaret Hamburg, another former FDA commissioner and signatory of the NEJM letter, has since 2020 earned $2.8 million as a member of the board of Alnylam Pharmaceuticals, which markets RNA interference (RNAi) technology.
Hamburg did not respond to a message on LinkedIn.
Most signatories disclosed income from biotech companies testing experimental cancer treatments. These products could face tighter scrutiny under Prasad, a hematologist-oncologist long wary of rubberstamping pricey oncology drugs — which Prasad points out often cause some toxicity — without plausible evidence of an improvement in quality of life or survival.
The former FDA commissioners disclosed ties to Sermonix Pharmaceuticals Inc.; OncoNano Medicine; incyclix; Nucleus Radiopharma; and N-Power, a contractor that runs oncology clinical trials.
Andrew von Eschenbach, who like Sharpless formerly served both as FDA commissioner and the head of the National Cancer Institute, disclosed stock in HistoSonics, a company with investments from Bezos Expeditions and Thiel Bio seeking FDA approval for ultrasound technology targeted at tumors.
Some FDA commissioners who signed onto the letter opposing changes to vaccine approvals have ties to biotechnology investment firms, namely McClellan, who consults Arsenal Capital; Janet Woodcock, who consults RA Capital Management; and Robert Califf, who owns stock in Population Health Partners.
Califf did not respond to an email requesting comment. Woodcock did not respond to requests for comment sent to two medical research advocacy groups with Woodcock on the board. Eschenbach did not respond to a LinkedIn message.
The two signatories without pharmaceutical ties may find their judgement challenged by the FDA investigation into COVID-19 vaccine deaths, having either implemented or formally defended the Biden administration’s headlong expansion of vaccines and boosters to healthy adults and children.
David Kessler executed Biden’s vaccination policy as chief science officer at the Department of Health and Human Services, helping to secure deals for shotswith Pfizer and Moderna.
Meanwhile Jane Henney chaired a National Academies of Sciences, Engineering, and Medicine report published in October 2025 that praised the performance of FDA and Centers for Disease Control and Prevention (CDC) vaccine surveillance during the pandemic — underwritten with CDC funding.
That assessment clashes with that of a Senate report, citing internal documents from FDA, finding that CDC never updated its vaccine surveillance tool “V-Safe” to include cardiac symptoms, despite naming myocarditis as a potential adverse event by October 2020, and that top officials in the Biden administration delayed warning pediatricians and other providers about the risk of myocarditis after their approval in some children in May 2021, months after Israeli health officials first detected it in February 2021. The Senate investigation named Woodcock, a signatory of the NEJM letter, as one of the FDA officials who slow-walked the warning.
The U.S. Department of Justice will not release the entirety of the federal government’s files on sex trafficker Jeffrey Epstein by the end of day Friday, failing to fully comply with a mandate from Congress.
DOJ will release several hundred thousand documents, however, Deputy Attorney General Todd Blanche said in a Fox News interview. He estimated that “several hundred thousand more” will be released “over the next couple of weeks.”
The delay, Blanche explained, is due to the significant number of redactions that the department must complete in order to protect the identifications of witnesses and victims in the files.
By failing to fully comply with a congressional edict, lawmakers would have grounds to impeach or hold U.S. Attorney General Pam Bondi in contempt of Congress.
Congress passed the Epstein Files Transparency Act on Nov. 18, which President Donald Trump signed into law the next day.
The bill, sponsored by Reps. Ro Khanna, D-Calif.; and Thomas Massie, R-Ky., requires that the U.S. Attorney General “make publicly available in a searchable and downloadable format all unclassified records, documents, communications, and investigative materials in the possession of the Department of Justice” that relate to Epstein and his close associate Ghislaine Maxwell.
“Any Justice Department official who does not comply with this law will be subject to prosecution for obstruction of justice,” Khanna vowed.
Epstein died in jail awaiting trial in 2019 and Maxwell is currently serving a 20-year prison sentence.
President Donald Trump, former president Bill Clinton, billionaire businessman Bill Gates, and dozens of other high-profile figures have received intense public scrutiny for their connections with Epstein and Maxwell.
